Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) - Wikidata - wikimedia - TriplyDB

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

http://www.wikidata.org/entity/Q34280885

about

Targeted therapies in CLL: mechanisms of resistance and strategies for management Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia Modeling Tumor Clonal Evolution for Drug Combinations Design Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Preventing clonal evolutionary processes in cancer: Insights from mathematical models.An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Mathematical models of breast and ovarian cancers.Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Molecular deregulation of signaling in lymphoid tumors.Recent advances in therapy of chronic lymphocytic leukaemia.Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.Effect of aspirin on tumour cell colony formation and evolution.Modeling the Subclonal Evolution of Cancer Cell Populations.Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study.

P2860

Q27002528-3E85184A-5F42-4DDF-9148-7161B820D392 Q28087672-36763AF7-F0A3-4649-9606-30DF64A72444 Q33590430-43700500-84C1-42F0-8CAF-9D42411E8644 Q33774517-1B529F3A-014C-4C0D-AA72-09A31EAAA8AF Q35895622-89F7CE57-43C1-48F4-8842-BF3124B99DF9 Q35978724-D452D0B3-AD8D-4856-B67F-64F6C9FF001A Q36925503-5C696127-F7FB-45F4-9A5F-84EF3E95BAB9 Q37014152-12753391-5A03-4994-A070-740A55F78CDA Q37397222-2045F4DF-7E21-4C4F-8741-9524846F9A63 Q38331701-18C23624-8D5C-4BCE-B91E-D68B12C5FACB Q38424403-D03900C7-723A-499E-935E-506C12C1794D Q38862525-8BAE06FF-95B0-4A80-AEBB-8951C69CE33D Q39010883-A5CDAAEF-62A4-42BD-A595-A20AF2F234FA Q39169789-7C611EE9-6EC0-455A-89FF-829865275939 Q40397638-40217921-8BAA-42FA-B538-487D06E676EB Q41169177-7A2D4E6E-9EED-4835-9ADC-DEB3FDE786CF Q42315534-A268A2FF-CFFC-446F-8AE3-A713A658EFA8 Q42383180-48623982-9904-4730-ABDB-E8DAB6BB5AF7 Q46074725-1688AA09-D840-411E-ADD7-872A99C52596 Q46244831-8839EEB4-8BF0-4C40-87AA-43837CE3754A Q46722923-0E155980-567F-41FB-8A0D-D8CF2C6458D9 Q49541273-4A52BEC1-B5F7-4C74-83A4-EB97034AB750 Q52684522-81BD9A2E-C7FD-4B2A-B13C-A5E603055624

P2860

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

http://www.wikidata.org/entity/Q34280885

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@ast

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@en

Evolution of ibrutinib resistance in chronic lymphocytic leukemia

@nl

type

label

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@ast

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@en

Evolution of ibrutinib resistance in chronic lymphocytic leukemia

@nl

prefLabel

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@ast

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@en

Evolution of ibrutinib resistance in chronic lymphocytic leukemia

@nl

P1433

Q34280885-5B84E7F3-33D7-4AFF-ABD1-FD297D047D53

P1476

Q34280885-2058D277-B42D-4766-9C09-254D8730BC0A

P2093

Q34280885-068C8DDE-A28C-43C4-8A46-B9F7C4ADF312

Q34280885-6DE1B2BC-6D94-449D-9C4E-488AB2F5CC18

Q34280885-EF43573B-BDB5-4A24-A8E6-3BF85465BD5D

P2860

Q34280885-1C9739DE-039C-462E-ADCF-8E259AC6A1E2

Q34280885-1EA2A187-CEBF-438E-B5DE-C7D73CC621AE

Q34280885-24C35F02-05AE-4878-8BDA-C14408870E13

Q34280885-28C93D03-B03A-4A65-BE3C-1A5D658690E5

Q34280885-358CDBC8-B576-4706-97D0-408197334D88

Q34280885-4BA7107F-3E50-48C6-98A4-151898DF19FF

Q34280885-4C4A30D2-B5CC-48CD-9B9F-EE2E35AD13B3

Q34280885-4C4D1FA9-4BBD-4481-ABC5-951BF591DCF0

Q34280885-53AC4533-77D2-410D-B81E-F9AD211EB4E6

Q34280885-59EC26C8-655F-4CE4-BADA-17731933B400

P304

Q34280885-7BD65EB6-37FC-418F-A0BF-C4A0D4981702

P31

Q34280885-607FCD1A-D8F7-436E-9316-EEED3C8E2C03

P356

Q34280885-EE8C6BB6-8FCE-45AE-AE41-3DBB4EAD46DF

P407

Q34280885-35D89406-3A42-4F4C-BFD2-CDE45E148139

P433

Q34280885-8E274C61-660A-4F3D-9DBD-2929107E9E3B

P478

Q34280885-1C2C9D16-5324-4DFF-A7F8-F7CB5A452F5A

P577

Q34280885-8BAB423F-8F8A-4D1A-AA2C-A4DCDD10F333

P698

Q34280885-A43988DE-9C94-4449-B7DB-DD6887B2E5F5

P921

Q34280885-5E2584DE-A15D-422A-9CCD-C876C8B763A3

Q34280885-F56874EF-A5C6-4CED-82A0-587DBC93E1EB

P932

Q34280885-7998833E-8659-458E-824E-53698FD77050

P356

PNAS.1409362111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

@en

P2093

Dominik Wodarz

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Natalia L Komarova

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Mutations in normal breast tissue and breast tumours

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

A simple algebraic cancer equation: calculating how cancers may arise with normal mutation rates.

P304

13906-13911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1409362111

http://www.w3.org/2001/XMLSchema#string

P407

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25201956

http://www.w3.org/2001/XMLSchema#string

P921

P932

4183279

http://www.w3.org/2001/XMLSchema#string